Department of Geriatrics, Clinical Laboratory, Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Department of Pathology, the First Affiliated Hospital of Hunan University of Medicine, Huaihua, Hunan Province, China.
Clin Chim Acta. 2017 Dec;475:152-156. doi: 10.1016/j.cca.2017.10.027. Epub 2017 Nov 6.
Recent studies have indicated that long non-coding RNA actin filament-associated protein 1 antisense RNA 1 (lncRNA AFAP1-AS1) was increased in non-small cell lung cancer and associated with unfavorable patient prognosis. AFAP1-AS1 also participates in promoting invasion and metastasis in non-small cell lung cancer cells. However, the diagnosis value of serum AFAP1-AS1 in non-small cell lung cancer was unclear. In this study, we aimed to explore whether circulating AFAP1-AS1 can be used as a diagnostic biomarker for non-small cell lung cancer.
The serum AFAP1-AS1 expression level in 126 non-small cell lung cancer patients and 60 healthy controls was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The concentrations of serum cyfra21-1 were detected through chemiluminescence method using the Roche Cobas e601. Receiver operating characteristic curve analysis was applied to assess the diagnostic value of serum AFAP1-AS1 and cyfra21-1 in non-small cell lung cancer.
The results demonstrated that AFAP1-AS1 expression level was significantly elevated in non-small cell lung cancer patients compared with that in normal controls (p=0.000). Serum AFAP1-AS1 could be used as molecular marker for distinguishing non-small cell lung cancer patients from healthy people with an area under the curve of 0.759 (95% confidence interval=0.692-0.826; p=0.000). The combination of FAP1-AS1 and cyfra21-1 showed that the area under the curve was 0.860 (95% confidence interval=0.808-0.912; p=0.000). Further analysis found that high serum AFAP1-AS1 expression levels correlated with distant metastasis (p=0.03), lymph node metastasis (p=0.017), poor clinical stage (p=0.019), and larger tumor size (p=0.015). Furthermore, AFAP1-AS1 was significantly upregulated in positive distant metastasis group (p=0.003), positive lymph node metastasis (p=0.017), poor clinical stage group (p=0.019), and larger tumor size group (p=0.015).
Serum AFAP1-AS1 could serve as an ideal combined biomarker for the diagnosis of non-small cell lung cancer.
最近的研究表明，长非编码 RNA 细丝相关蛋白 1 反义 RNA 1（lncRNA AFAP1-AS1）在非小细胞肺癌中升高，并与患者预后不良相关。AFAP1-AS1 还参与促进非小细胞肺癌细胞的侵袭和转移。然而，血清 AFAP1-AS1 对非小细胞肺癌的诊断价值尚不清楚。在本研究中，我们旨在探讨循环 AFAP1-AS1 是否可用作非小细胞肺癌的诊断生物标志物。
采用实时定量聚合酶链反应（qRT-PCR）检测 126 例非小细胞肺癌患者和 60 例健康对照者血清 AFAP1-AS1 表达水平。采用罗氏电化学发光法检测血清细胞角蛋白 19 片段 21-1（cyfra21-1）浓度。应用受试者工作特征曲线分析评估血清 AFAP1-AS1 和 cyfra21-1 在非小细胞肺癌中的诊断价值。
结果表明，与正常对照组相比，非小细胞肺癌患者 AFAP1-AS1 表达水平显著升高（p=0.000）。血清 AFAP1-AS1 可作为区分非小细胞肺癌患者和健康人的分子标志物，曲线下面积为 0.759（95%置信区间=0.692-0.826；p=0.000）。AFAP1-AS1 和 cyfra21-1 的联合检测曲线下面积为 0.860（95%置信区间=0.808-0.912；p=0.000）。进一步分析发现，高血清 AFAP1-AS1 表达水平与远处转移（p=0.03）、淋巴结转移（p=0.017）、不良临床分期（p=0.019）和较大肿瘤大小（p=0.015）相关。此外，在远处转移阳性组（p=0.003）、淋巴结转移阳性组（p=0.017）、临床分期不良组（p=0.019）和肿瘤较大组（p=0.015）中，AFAP1-AS1 明显上调。
血清 AFAP1-AS1 可作为非小细胞肺癌诊断的理想联合生物标志物。
